KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
KIORA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.38−0.02 (-0.83%)
Close on Oct 19, 2026
- Market cap
- $14.70M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -83.9% | -51.7% | |
| Return on assets | – | -54.0% | -35.7% | |
| Current ratio | 0.57 | 0.87 | 5.99 | |
| Debt to equity | – | 0.03 | – | |
| Interest coverage | – | -1640.9× | -642.8× | |
| Capex to revenue | 0.0% | 166.5% | – | |
| Diluted shares | 0M | 0M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kiora Pharmaceuticals generated $49.18M from operations and spent $180.91K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$49.18M
Used
$180.91K
Capital expenditure$180.91K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin22.4%
×Asset turnover0.64×
×Equity multiplier1.58×
=Return on equity, FY202422.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | 22.4% | 0.64× | 1.58× | 22.6% |
| FY2020 | -56901.7% | 0.00× | 1.55× | -83.9% |
| FY2019 | -264.2% | 0.22× | 1.57× | -91.2% |
| FY2018 | -654.2% | 0.12× | 4.08× | -308.5% |
| FY2017 | -3243.5% | 0.03× | -10.65× | 1171.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$10.84M
- Cash generatingOperating cash flow above zero-$9.96M
- Return on assets improvedROA up on the prior year26.2% → -29.7%
- Earnings backed by cashOperating cash flow above net income-$9.96M vs -$10.84M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.94 → 5.99
- No dilutionShare count did not rise4M → 4M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.17 → 0.00